Newleos Begins UK Trial of Anxiety Drug NTX-1955

Got story updates? Submit your updates here. ›

Newleos Therapeutics, a clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders, has announced the dosing of the first participant in a Phase 1b clinical trial of its investigational drug NTX-1955 in the United Kingdom. The trial is evaluating the safety, tolerability, and pharmacokinetics of NTX-1955 in adults with generalized anxiety disorder.

Why it matters

Generalized anxiety disorder is a common and debilitating mental health condition that affects millions of people worldwide. The development of new, innovative treatments like NTX-1955 could provide much-needed relief for those suffering from chronic anxiety and help address the significant unmet medical need in this area.

The details

The Phase 1b trial is a randomized, double-blind, placebo-controlled study that will enroll approximately 40 adults with generalized anxiety disorder. Participants will receive either NTX-1955 or a placebo over the course of several weeks, and the study will assess the safety, tolerability, and pharmacokinetic profile of the investigational drug.

• The first participant was dosed on April 1, 2026.

What’s next

Upon successful completion of the Phase 1b trial, Newleos plans to advance NTX-1955 into larger, late-stage clinical studies to further evaluate its safety and efficacy in treating generalized anxiety disorder.